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Migraine is a brain disorder affecting ~12% of the Caucasian population.  Genes involved in 
neurological, vascular and hormonal pathways have all been implicated in predisposing 
individuals to developing migraine.  The migraineur presents with disabling head pain and 
varying symptoms of nausea, emesis, photophobia, phonophobia and occasionally visual 
sensory disturbances.  Biochemical and genetic studies have demonstrated dysfunction of 
neurotransmitters: serotonin, dopamine and glutamate in migraine susceptibility.  Glutamate 
mediates the transmission of excitatory signals in the mammalian central nervous system 
which affect normal brain function including cognition, memory and learning.  The aim of 
this study was to investigate polymorphisms in the GRIA2 and GRIA4 genes which encode 
subunits of the ionotropic AMPA receptor for association in an Australian Caucasian 
population. 
Methods: 
Genotypes for each polymorphism were determined using High Resolution Melt analysis and 
the RFLP method.   
Results:  
Statistical analysis showed no association between migraine and the GRIA2 and GRIA4 
polymorphisms investigated. 
Conclusions: 
Although the results of this study showed no significant association between the tested GRIA 
gene variants and migraine in our Australian Caucasian population further investigation of 
other components of the glutamatergic system may help to elucidate if there is a relationship 





Migraine is a painful disorder of neurovascular origin with a substantial genetic involvement.  
Global prevalence estimates indicate ~12% (males 6%; females 18%) of Caucasian 
individuals suffer migraine throughout their lifetime 1, 2.  In middle adulthood migraine 
affects women three times more than men and is thought to be due to changes in ovarian 
hormones.  Migraine is a distressing disorder that disables the sufferer and interferes with 
social relationships creating a cycle of worry, fear and anxiety that has repercussions on 
family life.     
 
Migraine presents as a severe headache that can last 4 to 72 hours and can include symptoms 
of nausea, vomiting, photophobia and phonophobia and sometimes visual sensory 
disturbances 3.  Diagnosis is established by fulfilment of symptom-based criteria defined by 
the International Headache Society (IHS) 3.  Two main types of migraine are classified by the 
IHS, migraine with aura (MA) and migraine without aura (MO).  Migraine with aura patients 
are less common representing 30% of the total migraine population.  These patients in 
addition to experiencing a throbbing headache, also experience an aura before their headache 
that lasts from 5 minutes to less than 1 hour and consists of fully reversible visual, sensory or 
language symptoms 4.   
 
The onset of migraine with and without aura is shaped by both genetic and environmental 
variables.  Family pedigrees and twin studies have estimated hereditary factors to contribute 
between 34% and 57% to the aetiology of migraine this figure may vary in different 
populations 5.  Migraine is triggered by a complex cascade of chemical changes occurring 
between neurological and vascular tissues.  The innervation of the meninges by the 
trigeminovascular system and its nerve fibers has been implicated in the development of 
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headache6-8.  Cortical Spreading Depression (CSD) is an electrophysiological event that has 
also been implicated in headache particularly migraine with aura 9.  Imbalances in 
neurotransmitters including, serotonin, dopamine and glutamate, have been identified and 
hypothesised to contribute to the cellular hyperexcitable state exhibited by migraineurs 10.   
 
The biological components of these neurotransmitter systems including receptors and 
transporters have been studied at a genetic level in migraine pathogenesis with the aim of 
identifying genetic defects that could potentially lead to a higher susceptibility to migraine.  
Recently genetic studies have indicated that excess glutamate in the brain could play a role in 
the development of migraine 11-14.  Excess glutamate at the synapse is thought to contribute to 
the neuronal hyper-excitability state a mechanism possibly implicated in common migraine.  
Glutamate has been linked to physiological processes including trigeminovascular activation, 
central sensitization, allodynia and cortical spreading depression 15.  Glutamate is an 
important neurotransmitter that relays excitatory signals along the trigeminothalamic 
pathway16.   
 
Glutamatergic neurotransmission occurs via the interaction of glutamate with metabotropic 
and ionotropic receptors including Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionin 
acid (AMPA), kainate receptors (KA), and N-methyl-D-aspartate (NMDA) receptors 17.  The 
ionotropic AMPA receptors are constructed from four types of subunits coded by four 
separate genes designated as GluR1 (GRIA1), GluR2 (GRIA2), GluR3 (GRIA3), and GluR4 
(GRIA4) at chromosomal loci 5q33, 4q32, Xq24 and 11q24 respectively 17.  The GRIA 
subunits assemble to form ligand-gated ion channels in the plasma membrane permeable to 
Na+, K+ and Ca2+ quickly opening and closing in response to ligand (e.g. glutamate) binding.  
AMPA receptors are expressed in CNS glial cells and neurons where they relay fast 
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excitatory signals mediated by their interaction with glutamate 18.  AMPA receptors have 
been among the most studied in regard to a variety of neurological diseases including 
schizophrenia 19-21.  Dysfunctional conductance of these ion channels due to genetic mutation 
may result in a disturbed balance of synaptic activity which could pose significant 
consequences to normal physiological functioning in vivo and play a key role in the 
pathophysiology of migraine.  Ion channel genes have been implicated in the rare autosomal 
inherited (FHM) providing good impetus for pursuing these variants 22.  
 
Biochemical studies undertaken in the last 20 years have demonstrated differences in the 
levels of glutamate in a range of biological fluids of migraine patients when compared to 
controls particularly in those with aura 10, 23, 24. Animal experiments have shown that 
glutamate can affect Spreading Depression and that consumption of glutamate-rich food can 
provoke migraine attacks in predisposed subjects 10.  Recently Gonzalez de la Aleja et al., 
2013 quantified the metabolites glutamate and glutamine by proton magnetic resonance 
spectroscopy in neurons and astrocytes in the occipital lobe of a group of women with 
migraine 25.  Glutamate and glutamine are important in neurotransmission and energy 
metabolism.  In this study a more elevated Glu/Gln ratio was found in the brains of 
migraineurs during the pain-free interval which the authors suggest could facilitate CSD in 
the occipital lobe of migraineurs 25.  They caution the study is limited by a small sample size 
(27 migraineurs and 19 controls) but that a statistical difference in the Glu/Gln ratio between 
groups was detected 25.  Although linkage with a known genetic disorder has not been 
established, low function of glutamate in neurons is associated with schizophrenia 19-21 and 
some neurological disorders are accompanied by the appearance of antibodies or autoantigen 




More research investigating the components of the glutamatergic system is necessary to 
confirm or rule out a role in either causing or predisposing to migraine when mutated.  In a 
previous study Formicola et al., 2010 investigated subunits of the AMPA receptor GRIA1-4 
and identified a positive association with 2 SNPs in GRIA1 (rs548294 MO allelic P=0.008, 
rs2195450 MA allelic P=0.0005) and 1 SNP in the GRIA3 promoter (rs3761555 MA Females 
allelic P=0.003) in an Italian population 13.  In this study we investigated if polymorphisms, 
different to those tested by Formicola and Colleagues, in the GRIA2 and GRIA4 genes 




Materials and methods 
Study Population 
 
This research was approved by Griffith University's Ethics Committee for experimentation on 
human subjects.  The study population was composed of 284 migraine cases and 284 age- (± 
5 years), sex and ethnicity matched controls.  Each study participant gave informed consent 
and provided a sample of whole blood from which genomic DNA was extracted.  The 
migraine population was recruited from the Gold Coast Hospital, Southport and all samples 
were obtained from patients residing in the South East Queensland Region of Australia.  
Migraine diagnosis was overseen by an experienced clinical neurologist based on responses 
provided in a questionnaire in accordance with the International Headache Society (IHS) 
criteria 3.  Migraineurs were diagnosed as having either migraine with aura or migraine 
without aura.  The matched control group was obtained via the Genomics Research Centre 
Clinic, Southport, and comprised of healthy Caucasian controls certified as having no history 








DNA was extracted from white blood cells following a salting out method as described by 
Miller et al.27, 20ng of DNA was used for genotyping experiments.  Three polymorphisms in 
GRIA2 and four polymorphisms in GRIA4 were genotyped for all cases and controls.  
Detailed information regarding polymorphisms genotyped in the GRIA2 and GRIA4 genes 
and a summary of assay conditions and primer sequences for each polymorphism are listed in 
Table 1.  PCR buffers, MgCl2, Go-Taq polymerase were from Promega Corp., (Madison, WI, 
USA), dNTPs, restriction enzymes, and enzyme buffers were from New England Biolabs, 
(Ipswich, MA, USA) and SYTO9 dye was from (Invitrogen, Melbourne, Australia).  Specific 
protocol and assays for each polymorphism are described in detail below.  Primers were 
obtained from IDT (Integrated DNA Technologies) in sequencing quality at a concentration 
of 100µM in liquid form.  Aliquots for each set of primers were made at a concentration of 
5µM in H2O for use in PCR optimization experiments.  PCRs were run on a combination of 
Applied Biosystems Veriti® Themal Cyclers, Corbett Robotics Palm Cyclers, Qiagen 





Polymorphisms selection and Genotyping 
Selection of SNPs was undertaken in the program Haploview v4.2 28.  HapMap release #28 
CEU SNP genotype data was downloaded for each candidate gene and analysed for LD.  The 
aim of this analysis was to exclude SNPs that were in LD with eachother but to select SNPs 
that would cover different LD blocks and still be informative across each tested gene.  SNPs 
chosen were sampled in a European-Caucasian population and were located in intronic 









The human GRIA2 gene codes for one of four subunits of the AMPA receptor and maps to 
chromosome 4q32.1 and spans a genomic region of about 143 kb.  The polymorphisms 
rs4131622, rs9307961 and rs4403097 were genotyped by PCR followed by HRM analysis.  
The PCR protocol was as follows: 1X PCR buffer, 2.0mM MgCl2, 0.2mM dNTPs, 0.2µM 
forward primer, 0.2µM reverse primer, 1.5µM SYTO9, 0.35U GoTaq in a 15µl reaction.  The 
primer sequences were designed manually for each marker and checked for specificity using 
NCBI Primer-BLAST to ensure the DNA sequence of each primer set was unique and 
amplified the correct region of the gene (http://www.ncbi.nlm.nih.gov/BLAST/).   
The PCR followed by HRM analysis was conducted on a Qiagen Rotor-Q and the 
thermocycling conditions for rs4403097 consisted of: 95◦C for 5mins, then 95◦C for 5 
seconds and 60◦C for 10 seconds for 45 cycles.  PCR products were melted from 65◦C to 
75◦C at 0.1◦C increments every 2 seconds.  Amplicon Tm occurred at 70◦C and three 
separate melt curves were obtained corresponding to the three genotypes CC, CT, and TT. 
 
Thermocycling conditions for rs9307961 consisted of: 95◦C for 5mins, then 95◦C for 5 
seconds and 45◦C for 10 seconds for 45 cycles.  PCR products were melted from 68◦C to 
78◦C at 0.1◦C increments every 2 seconds.  Amplicon Tm occurred at 73◦C and three 
separate melt curves were obtained corresponding to the three genotypes GG, GT, and TT. 
 
Thermocycling conditions for rs4131622 consisted of: 95◦C for 5mins, then 95◦C for 5 
seconds and 50◦C for 10 seconds for 45 cycles.  PCR products were melted from 70◦C to 
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80◦C at 0.1◦C increments every 2 seconds.  Amplicon Tm occurred at 80◦C and three 








The human GRIA4 gene codes for one of four subunits of the AMPA receptor and maps to 
chromosome 11q22.3 and spans a genomic region of about 370kb.  The GRIA4 rs10895856, 
GC polymorphism was genotyped by polymerase chain reaction (PCR) followed by 
restriction fragment length polymorphism (RFLP) analysis.  The PCR thermocycling 
conditions were as follows: 95◦C for 3mins, then 94◦C for 40 seconds, 45◦C for 40 seconds, 
and 72◦C for 40 seconds for 30 cycles, followed by a final extension step of 72◦C for 5 
minutes.  The 124pb PCR products were electrophoresed on a 2% agarose gel containing 
stained with ethidium bromide for 30mins at 90V, and then visualised under ultraviolet light.  
10 µL of PCR product was then digested with 0.8U of HpyCH4V and 1X NEB Buffer 4 at 
37◦C for 16 hrs.  Restriction digest products were electrophoresed in a 4 % agarose gel for 50 
min at 70 V, and visualised under ultraviolet light.  HpyCH4V digestion of fragments 
containing the G allele produced two fragments of 78bp and 46bp while fragments containing 
the C allele remained undigested 124pb by HpyCH4V. 
 
The following polymorphisms: rs1938966, rs10128540, rs10502059 were genotyped by PCR 
followed by HRM analysis.  The PCR followed by high resolution melting analysis was 
conducted on a Qiagen Rotor-Q (Qiagen, Doncaster, VIC, Australia).  Thermocycling 
conditions for rs10128540 consisted of: 95◦C for 5mins, then 95◦C for 5 seconds and 56◦C 
for 10 seconds for 45 cycles.  PCR products were melted from 70◦C to 80◦C at 0.1◦C 
increments every 2 seconds.  Amplicon Tm occurred at 73◦C and three separate melt curves 




Thermocycling conditions for rs10502059 consisted of: 95◦C for 5mins, then 95◦C for 5 
seconds and 58◦C for 10 seconds for 45 cycles.  PCR products were melted from 72◦C to 
82◦C at 0.1◦C increments every 2 seconds. Amplicon Tm occurred at 80◦C and three separate 
melt curves were obtained corresponding to the three genotypes AA, AG, and GG. 
 
Thermocycling conditions for rs1938966 consisted of: 95◦C for 5mins, then 95◦C for 5 
seconds and 58◦C for 10 seconds for 45 cycles.  PCR products were melted from 74◦C to 
84◦C at 0.1◦C increments every 2 seconds.  Amplicon Tm occurred at 70◦C and three 
separate melt curves were obtained corresponding to the three genotypes AA, AG, and GG. 
 
Positive controls of DNA samples with known genotypes were genotyped on the ABI-3130 
Genetic Analyser (Applied Biosystems) to validate the genotypes obtained by the HRM 














Table 1 SNP and assay information. 








F:  5’ TGCAGAGCAAATGCTATTACAAG 3’ 
R:  5’ GCTGCCATTAACATTTCAATCA 3’ 
150bp N/A N/A 




F:  5’ TAAGAGGCATGACATGAGCT 3’ 
R:  5’ AATTCTTGATTTAACATCTAAAGG 3’ 
120bp N/A N/A 




F:  5’ TGTAATCTTGCCCCCAAAGT 3’   
R:  5’ TCTACATAGATCAAATGCTTTTGTG 3’   
106bp N/A N/A 
GRIA4 11q22.3 rs10895856  
 
G/C PCR-RFLP  
 
F:  5’ CAGAACTCGGAACCCCAATAC 3’ 
R: 5’ GTATACATCATAGGTTCAAGCATATGG 3’ 
124bp HpyCH4V C-124bp, G-
78bp, 46bp 




F:  5’ TTGGAGAAGGCGACCTACAA 3’ 
R:  5’ ACCCCACCCTAGCACCTTTC 3’ 
107bp N/A N/A 




F:  5’ CTTCTGTCCCTAGAAATTCCAGG 3’ 
R:  5’ ACAACTGAACCTGAAATACCACAG 3’ 
125bp N/A N/A 




F:  5’ TAAGGACGGACTGTTGTACTGG 3’ 
R:  5’ TGACCCTATTATGTTTACCCAGAA 3’ 
102bp N/A N/A 
AA: amino acid; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HRM: high resolution melt. 
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Statistical Analysis  
The genotypes for migraine cases and controls were in Hardy Weinberg Equilibrium (HWE) 
for each of the SNPs examined (p>0.05).  Genotype and allele frequencies were compared 
between case and control groups for each marker using the Chi-square (χ2) test, with two and 
one degrees of freedom, respectively.  The Statistical Package for Social Sciences (SPSS 
version 21.0) was used for statistical analyses.  The results were also subdivided into MA and 








The aim of this study was to determine if polymorphisms in the GRIA2 and GRIA4 genes 
contribute to migraine susceptibility in an Australian case-control cohort.  The study 
population consisted of 284 migraine cases and 284 age- (± 5 years), sex and ethnicity 
matched healthy controls.  This migraine population had a higher proportion of MA cases 
compared to MO which typically accounts for a third of total migraineurs.  We chose to 
investigate polymorphisms in subunits of the AMPA receptor as some SNPs within this gene 
were previously found associated in a study by Formicola et al., 2010 13.   
SNP selection was conducted in Haploview for the European-Caucasian population to select 
SNPs to genotype for each gene.  The genotypes for six SNPs were determined by HRM 
whilst one SNP was determined by the RFLP method of genotyping.  Genotypes were 
determined by interpreting shifts in the amplification profiles and product melt curves of the 
genotyped samples using the Rotor-Gene software.  The raw genotype data was individually 
checked against baseline genotypes from positive controls at a confidence threshold of 70% 
and any ambiguous samples were identified and where possible these individuals were re-
genotyped or genotypes were excluded from the analysis as errors.  Three distinct melt curves 
were obtained allowing discrimination of three genotypes. 
Chi-square (χ2) analysis was performed to determine if significant differences existed in the 
genotype and allele frequencies in the migraine population versus controls as well as the 
subgroups of migraineurs with aura versus controls and migraineurs without aura versus 






Rs4131622, rs9307961, rs4403097 are SNPs that fall in different introns of the GRIA2 gene.  
Genotypic and allelic frequencies obtained for these polymorphisms are shown in Table 2 
and 3 respectively. Genotype frequencies between cases and controls were not significantly 
different, MA and controls, nor MO and controls.  There was also no significant difference in 
the allele frequencies between cases and controls, MA and controls, nor MO and controls.   
 
Rs1938966, rs10128540, rs10502059, rs10895856 are SNPs that fall in different introns of 
the GRIA4 gene and results obtained for these are shown in Table 3.  Genotype frequencies 
between cases and controls were not significantly different, MA and controls, nor MO and 
controls.  There was also no significant difference in the allele frequencies between cases and 
controls, MA and controls, nor MO and controls.   
 
Chi square analysis revealed a negative association between migraine and the GRIA genes.  
The minor allele frequency was demonstrated to be similar to the reported frequency in 
HapMap.  Genotype proportions did not deviate from conditions expected under Hardy 










Table 2     Genotyping results of GRIA2. 
GRIA2 
rs4403097 
Genotypes  Alleles  
TT CT CC Total T C Total 
Controls 52 (21.7%) 118 (49.3%) 69 (28.9%) 239 222 (46.4%) 256 (53.6%) 478 
Cases 48 (20.8%) 103 (44.6%) 80 (34.6%) 231 199 (43.0%) 263 (57%) 462 
 χ2 = 1.85, P = 0.39  χ2 =1.08, P = 0.29  
MA 32 (21.9%) 65 (44.5%) 49 (33.6%) 146 129 (44.2%) 163 (55.8%) 292 
 χ2 = 1.10, P = 0.57  χ2 = 0.38, P = 0.54  
MO 16 (18.8%) 38 (44.7%) 31 (36.5%) 85 70 (41.2%) 100 (58.8%) 170 
 χ2 = 1.71, P = 0.42  χ2 = 1.41, P = 0.23  
GRIA2 
rs9307961 
Genotypes  Alleles  
TT GT GG Total T G Total 
Controls 24 (9.8%) 106 (42.7%) 118 (47.5%) 248 154 (31.0%) 342 (68.9%) 496 
Cases 29 (12.6%) 99 (42.8%) 103 (44.6%) 231 157 (34%) 305 (66.0%) 462 
 χ2 = 1.13, P = 0.56  χ2 = 0.94, P = 0.33  
MA 20 (14.2%) 49 (34.7%) 72 (51.1%) 141 89 (31.6%) 193 (68.4%) 282 
 χ2 = 3.28, P = 0.19  χ2 = 0.02, P = 0.88  
MO 9 (10%) 50 (55.6%) 31 (34.4%) 90 68 (37.8%) 112 (62.2%) 180 
 χ2 = 4.94, P = 0.08  χ2 = 2.71, P = 0.10  
GRIA2 
rs4131622 
Genotypes  Alleles  
AA CA CC Total C A Total 
Controls 30 (12%) 110 (43.8%) 111 (44.2%) 251 332 (66.1%) 170 (33.8%) 502 
Cases 32 (13.5%) 100 (42.0%) 106 (44.5%) 238 312 (65.5%) 164 (34.4%) 476 
 χ2 = 0.31, P = 0.85  χ2 = 0.04, P = 0.84  
MA 23 (15.8%)  52 (35.6%) 71 (48.6%) 146 194 (66.4%) 98 (33.6%) 292 
 χ2 = 2.91, P = 0.23  χ2 = 0.01, P = 0.93  
MO 9 (9.8%) 48 (52.2%) 35 (38.0%) 92 118 (64.1%) 66 (35.9%) 184 
 χ2 = 1.90, P = 0.38  χ2 = 0.24, P = 0.62  
 
MA — migraine with aura, MO — migraine without aura. 






Table 3     Genotyping results of GRIA4. 
GRIA4 
rs10128540 
Genotypes  Alleles  
TT CT CC Total T C Total 
Controls 57 (22.6%) 131 (52%) 64 (25.4%) 252 245 (48.6%) 259 (51.4%) 504 
Cases 65 (25.7%) 115 (45.5%) 73 (28.8%) 253 245 (48.4%) 261 (51.6%) 506 
 χ2 = 2.15, P = 0.34  χ2 = 0.00, P = 0.95  
MA 36 (23.5%) 71 (46.4%) 46 (30.1%) 153 143 (46.7%) 163 (53.3%) 306 
 χ2 = 1.39, P = 0.49  χ2 = 0.27, P = 0.60  
MO 29 (29%) 44 (44%) 27 (27%) 100 102 (51%) 98 (49%) 200 
 χ2 = 2.18, P = 0.33  χ2 = 0.33, P = 0.56  
GRIA4 
rs10895856 
Genotypes  Alleles  
CC GC GG Total G C Total 
Controls 66 (26.6%) 124 (50%) 58 (23.4%) 248 256 (51.6%) 240 (48.4%) 496 
Cases 72 (28.8%) 123 (49.2%) 55 (22.0%) 250 267 (53.4%) 233 (46.6%) 500 
 χ2 =  0.34, P = 0.84  χ2 =  0.32, P = 0.57  
MA 42 (27.3%) 81 (52.6%) 31 (20.1%) 154 165 (53.6%) 143 (46.4%) 308 
 χ2 = 0.60, P = 0.74  χ2 =  0.29, P = 0.58  
MO 30 (31.2%) 42 (43.8%) 24 (25.0%) 96 102 (53.1%) 90 (46.9%) 192 
 χ2 =  1.17, P = 0.55  χ2 = 0.13, P = 0.72  
GRIA4 
rs10502059 
Genotypes  Alleles  
AA GA GG Total G A Total
Controls 61 (24%) 133 (52.4%) 60 (23.6%) 254 253 (49.8%) 255 (50.2%) 508 
Cases 53 (21.5%) 121 (49%) 73 (29.6%) 247 267 (54%) 227 (46%) 494 
 χ2 = 2.3, P = 0.31  χ2 = 1.81, P = 0.17  
MA 28 (18.8%) 77 (51.7%) 44 (29.5%) 149 165 (55.7%) 131(44.3%) 296 
 χ2 = 2.77, P = 0.24  χ2 = 2.64, P = 0.10  
MO 25 (25.5%) 44 (44.9%) 29 (29.6%) 98 102 (52%) 94 (48%) 196 
 χ2 = 1.84, P = 0.39  χ2 = 0.28, P = 0.59  
GRIA4 
rs1938966 
Genotypes  Alleles  
AA GA GG Total G A Total
Controls 73 (28.9%) 128 (50.7%) 51 (20.2%) 252 274(54.4%) 230 (45.6%) 504 
Cases 70 (28.1%) 121 (48.6%) 58 (23.2%) 249 261 (52.4%) 237 (47.6%) 498 
 χ2 = 0.69, P = 0.70  χ2 = 0.38, P = 0.53  
MA 41 (27.2%) 76 (50.3%) 34 (22.5%) 151 158 (52.3%) 144 (47.7%) 302 
 χ2 =  0.35, P = 0.84  χ2 = 0.32, P = 0.57  
MO 29 (29.6%) 45 (45.9%) 24 (24.5%) 98 103 (52.6%) 93 (47.4%) 196 
 χ2 =  0.94, P = 0.62  χ2 = 0.19, P = 0.66  
 
MA — migraine with aura, MO — migraine without aura. 
p-Values were calculated by χ2-analysis, significance was taken at p≤0.05. 
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The major excitatory neurotransmitter of the brain, glutamate and the receptors and 
transporters upon which it acts are intimately involved in migraine processes including 
cortical spreading depression, trigeminovascular activation and central sensitization 15.  X-ray 
crystal structures of glutamate receptors have defined structure-function relationships by 
revealing which domains are involved in binding to agonists and antagonists providing 
insight into the mechanism of action of glutamate receptor antagonists 29-31.  Targeting the 
glutamatergic system may be an alternative non-vasoactive approach to the future treatment 
of migraine given the efficacy of glutamate receptor antagonists and that the multitude of 
currently prescribed drugs often produce variable patient responses 13, 32.  There is indirect 
evidence of glutamate involvement in largegenome-wide association studies utilizing large 
population cohorts.  A few genes affecting glutamatergic homeostasis (PGCP, MTDH14 and 
LRP115) and a cation channel (TRPM8) have stood out as statistically significant 14, 33.   
 
In light of the positive findings reported by Formicola et al., 2010 whereby some SNPs in the 
GRIA1 and GRIA3 genes which encode subunits of the AMPA receptor were found 
associated with migraine in an Italian population of 250 migraineurs and 260 controls we 
decided to explore further variation in the GRIA2 and GRIA4 subunits 13.  In the Formicola et 
al., 2010 study the association reported in the GRIA3 gene is interesting as this locus was also 
identified in two large Australian Caucasian families by our research group and is within a 
migraine susceptibility region Xq24-q28 34, 35.  The SNPs studied by Formicola et al., 2010 
were located in regulative regions of each gene where they may affect gene expression of the 
AMPA receptor.  GRIA3 has also been identified as a susceptibility gene in female patients 
with schizophrenia 19.  A recent study by Maher et al., 2013 replicated the  Formicola et al., 
2010 result of a positive association in the GRIA3 promoter polymorphism (rs3761555) in an 
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Australian migraine case-control cohort 11.  This replication study was performed in 454 
controls and 452 cases and identified a significant association in the MA subtype (Allele P = 
0.008) 11.  Confirmation of the GRIA3 locus by an independent group in a bigger and 
ethnically different population adds evidence to the hypothesis that dysfunction of glutamate 
homeostasis may be at the heart of susceptibility to migraine.  Also because of the genetic 
heterogeneity of migraine in people of different cultures replication of positive results in 
populations of different ethnicity is needed to determine if the association is indeed valid and 
ancestry specific or common.   
In the present association study we utilized an age (+/- 5yrs), gender and ethnicity matched 
Australian Caucasian population composed of 284 migraine cases diagnosed with one of two 
migraine subtypes, MA or MO matched to 284 healthy controls.  Study participants were 
recruited from the South East Queensland Region of Australia and our study population 
consisted of a slightly higher proportion of MA cases.  In this study, we investigated 
polymorphisms in the GRIA2 and GRIA4 genes of the ionotropic AMPA receptor to explore 
their potential role in susceptibility to migraine.   
Statistical analysis of the GRIA markers revealed no significant difference between 
genotyped migraineurs and the matched control group with regard to genotype frequencies 
and allele frequencies (Table 2 and Table 3).  Furthermore, no significant difference resulted 
when the migraine population was subdivided by gender into male and female groups (data 
not shown) and disease subtypes of MA and MO.    While an association between migraine 
and the tested GRIA gene variants was not detected in this population given the importance of 
the glutamatergic system and its involvement in biological processes in the brain it is likely 
that perhaps other genes coding for other components of this system could play a role.  
However, as there are no studies examining the effect of other components of the 
26 
 
glutamatergic system including kainate (KA) and N-methyl-D-aspartate (NMDA) and 
metabotropic receptors as well as EAAT transporters and enzymes that cycle glutamate we 
cannot exclude the possibility that these could be contributing to migraine aetiology and this 




In summary, although the results of this study did not provide significant association to the 
GRIA2 and GRIA4 genes with migraine risk in our migraine population additional variants in 
genes regulating glutamate pathways in the CNS are worthy of analysis.  Future studies will 
continue to build a gene profile of the complex common migraine disorder and help to 
provide new drug targets to research.  The identification of migraine susceptibility genes 
remains an important task in this population that could contribute to understanding the 
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